Industry / Slovenia

Krka Enters Acquisition Market

November 2007 | Industry News

Printable version
Bookmark

Slovenian drugmaker Krka is to make its first venture into Western Europe with the planned acquisition for German generics firm TAD Pharma in a deal reported to be worth EUR97mn (US$142.48mn).

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Krka Equity View Remains Neutral Over The Medium Term

Industry / Slovenia BMI View: Our equity view of Slovenian company Krka remains neutral, but with some upside potential since our previous analysis. Despite the company's exposure to high-growth pharmaceutical markets, Krka...

July 2011

Lek Expands Biosimilar Production

Industry / Slovenia Slovenian pharmaceutical company Lek, a division of Novartis's generic arm Sandoz, has opened a new US$3.8mn biopharmaceutical production facility to produce biosimilar epoetin alfa. Sandoz markets epoetin...

March 2010

New Health Services Act To Improve Efficiencies

Industry / Slovenia The Slovenian government approved a draft Health Services Act in March 2010, laying the groundwork for system reform in the country. The act introduces a number of reforms that will reorganise the provision...

March 2010

Strong Growth In Western Europe For Krka

Industry / Slovenia Half-yearly results from Slovenian pharmaceutical firm Krka have highlighted strong performance in the company's Western Europe and Overseas (which includes any markets outside of Europe) markets, increasing...

August 2008

2004 Accession States Lag Behind EU15 In Healthcare

Industry / Slovenia Slovenia is the healthiest EU newcomer, according to a study on eliminating inequalities in health in the EU, presented in Ljubljana on 16 June 2008. The study, which assessed the ten 2004 accession...

June 2008